MacroGenics (MGNX) News Today $1.49 -0.08 (-5.10%) Closing price 04:00 PM EasternExtended Trading$1.48 -0.01 (-0.67%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGNX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period MacroGenics, Inc. (NASDAQ:MGNX) Shares Sold by Vestal Point Capital LPVestal Point Capital LP lessened its holdings in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 66.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 280,000 shares of the biopharmaceutical companMay 21 at 8:23 AM | marketbeat.com6MGNX : 4 Analysts Assess Macrogenics: What You Need To KnowMay 20 at 9:21 PM | benzinga.comLeerink Partnrs Predicts Reduced Earnings for MacroGenicsMay 18 at 1:35 AM | americanbankingnews.comDimensional Fund Advisors LP Has $2.33 Million Position in MacroGenics, Inc. (NASDAQ:MGNX)Dimensional Fund Advisors LP decreased its holdings in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 18.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 717,288 shares of the biopharmaceutical company's stock after sMay 17, 2025 | marketbeat.comMacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial ResultsMay 16, 2025 | finanznachrichten.deEarnings Release: Here's Why Analysts Cut Their MacroGenics, Inc. (NASDAQ:MGNX) Price Target To US$4.50May 16, 2025 | finance.yahoo.comBrokerages Set MacroGenics, Inc. (NASDAQ:MGNX) Target Price at $7.43May 15, 2025 | americanbankingnews.comMacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comA Look at Macrogenics's Upcoming Earnings ReportMay 12, 2025 | benzinga.comMacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from AnalystsShares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have received an average recommendation of "Hold" from the nine analysts that are currently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation, two have given a buy recommendation aMay 12, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Decreases Holdings in MacroGenics, Inc. (NASDAQ:MGNX)Price T Rowe Associates Inc. MD lowered its holdings in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 61.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 485,987 shares of the biopharmaceutical company's stock after selling 768,249 shaMay 11, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Makes New Investment in MacroGenics, Inc. (NASDAQ:MGNX)Schonfeld Strategic Advisors LLC bought a new stake in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 857,505 shares of the biopharmaceuticalMay 7, 2025 | marketbeat.comMacroGenics Announces Date of First Quarter 2025 Financial ResultsMay 6, 2025 | globenewswire.comMacroGenics (MGNX) to Release Earnings on ThursdayMacroGenics (NASDAQ:MGNX) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-macrogenics-inc-stock/)May 3, 2025 | marketbeat.comMacroGenics to Participate in Upcoming Investor ConferenceMay 1, 2025 | globenewswire.comRenaissance Technologies LLC Raises Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)Renaissance Technologies LLC boosted its position in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 69.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 538,523 shares of theApril 29, 2025 | marketbeat.comMacroGenics (NASDAQ:MGNX) Shares Pass Below 200 Day Moving Average - Should You Sell?MacroGenics (NASDAQ:MGNX) Shares Cross Below 200 Day Moving Average - Here's What HappenedApril 27, 2025 | marketbeat.comJPMorgan Chase & Co. Acquires 221,905 Shares of MacroGenics, Inc. (NASDAQ:MGNX)JPMorgan Chase & Co. grew its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 68.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 546,807 shares of the biopharmaceutical company's stoApril 27, 2025 | marketbeat.comWasatch Advisors LP Raises Stake in MacroGenics, Inc. (NASDAQ:MGNX)Wasatch Advisors LP lifted its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 37.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,488,493 shares of the biopharmaceutical company's stockApril 19, 2025 | marketbeat.comMacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of "Hold" from BrokeragesShares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have earned a consensus rating of "Hold" from the eleven ratings firms that are presently covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold recommendation, two have assigned a buy recApril 17, 2025 | marketbeat.comMacroGenics (NASDAQ:MGNX) Stock Price Crosses Below Two Hundred Day Moving Average - What's Next?MacroGenics (NASDAQ:MGNX) Stock Crosses Below Two Hundred Day Moving Average - Time to Sell?April 10, 2025 | marketbeat.comQ1 Earnings Forecast for MacroGenics Issued By HC WainwrightMacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Stock analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for shares of MacroGenics in a report released on Tuesday, March 25th. HC Wainwright analyst R. Burns now anticipates that the biopharmaceutical company will earn (March 28, 2025 | marketbeat.comMacroGenics (NASDAQ:MGNX) Price Target Lowered to $2.00 at HC WainwrightHC Wainwright dropped their target price on shares of MacroGenics from $4.00 to $2.00 and set a "neutral" rating on the stock in a report on Tuesday.March 26, 2025 | marketbeat.comMacroGenics price target lowered to $2 from $4 at H.C. WainwrightMarch 25, 2025 | markets.businessinsider.comMacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by BrokeragesShares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have been given an average rating of "Hold" by the eleven research firms that are covering the stock, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold recommendation, two have assigned a buy recommendatioMarch 23, 2025 | marketbeat.comMacroGenics (NASDAQ:MGNX) Rating Lowered to "Hold" at StockNews.comStockNews.com cut shares of MacroGenics from a "buy" rating to a "hold" rating in a research report on Friday.March 22, 2025 | marketbeat.comMacroGenics Provides Update on Corporate Progress and 2024 Financial ResultsMarch 22, 2025 | finance.yahoo.comMacroGenics (NASDAQ:MGNX) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPSMacroGenics (NASDAQ:MGNX - Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. The company had revenue of $49.40 million during the quarter, compared to analysts' expectations of $34.17 million.March 22, 2025 | marketbeat.comQ4 2024 MacroGenics Inc Earnings CallMarch 21, 2025 | uk.finance.yahoo.comBarclays Sticks to Their Buy Rating for MacroGenics (MGNX)March 21, 2025 | markets.businessinsider.comMacroGenics (MGNX) Receives a Hold from Stifel NicolausMarch 21, 2025 | markets.businessinsider.comMacroGenics (MGNX) Gets a Hold from TD CowenMarch 21, 2025 | markets.businessinsider.comMacroGenics (MGNX) Q4 2024 Earnings Call TranscriptMarch 21, 2025 | msn.comMacroGenics, Inc. (MGNX) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comMacroGenics (MGNX) to Release Quarterly Earnings on ThursdayMacroGenics (NASDAQ:MGNX) will be releasing earnings after the market closes on Thursday, March 20, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=673061)March 13, 2025 | marketbeat.comMacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference CallMarch 6, 2025 | globenewswire.comMacroGenics CEO departure date extended amid search for successorFebruary 28, 2025 | uk.investing.comMacroGenics: Stacking Up A Lot Of HeadwindsFebruary 27, 2025 | seekingalpha.comMacroGenics to Participate in Upcoming Investor ConferencesFebruary 27, 2025 | globenewswire.comMacroGenics (NASDAQ:MGNX) Stock Crosses Below 200-Day Moving Average - Here's What HappenedMacroGenics (NASDAQ:MGNX) Shares Pass Below 200-Day Moving Average - Time to Sell?February 22, 2025 | marketbeat.comMacrogenics IncFebruary 18, 2025 | money.usnews.comThe past year for MacroGenics (NASDAQ:MGNX) investors has not been profitableFebruary 17, 2025 | finance.yahoo.comMacrogenics Stock Hits 52-Week Low at $2.91 Amid Sharp DeclineFebruary 3, 2025 | msn.comMacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from BrokeragesShares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have earned a consensus recommendation of "Hold" from the eleven brokerages that are presently covering the stock, MarketBeat reports. Eight equities research analysts have rated the stock with a hold recommendation, two have assigned a bFebruary 3, 2025 | marketbeat.comJPMorgan Chase & Co. Reduces Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)JPMorgan Chase & Co. cut its position in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 32.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 324,902 shares of the biopharmaceutical company's stock after selling 155,359 shares during the period.January 26, 2025 | marketbeat.comMacrogenics Stock Hits 52-Week Low at $2.95 Amid Market ChallengesJanuary 18, 2025 | msn.comMacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by AnalystsMacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) has earned an average recommendation of "Hold" from the eleven analysts that are covering the company, MarketBeat.com reports. Eight analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy raJanuary 9, 2025 | marketbeat.comMacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Recommendation of "Hold" by BrokeragesShares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have received a consensus recommendation of "Hold" from the eleven research firms that are presently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating, two have assigned a buyDecember 15, 2024 | marketbeat.comMGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmDecember 10, 2024 | globenewswire.comJacobs Levy Equity Management Inc. Buys 147,438 Shares of MacroGenics, Inc. (NASDAQ:MGNX)Jacobs Levy Equity Management Inc. grew its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 35.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 566,328 shares of the biopharmaceutical company's stock after acquiring aDecember 8, 2024 | marketbeat.com Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address MGNX Media Mentions By Week MGNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MGNX News Sentiment▼-0.070.65▲Average Medical News Sentiment MGNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MGNX Articles This Week▼117▲MGNX Articles Average Week Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Prothena News Autolus Therapeutics News Kamada News Verve Therapeutics News Oruka Therapeutics News Revance Therapeutics News Sana Biotechnology News Fulcrum Therapeutics News ABIVAX Société Anonyme News Rapport Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MGNX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MGNX Stock Free MGNX Stock Alerts